Promising functional readouts of immunity in a blood-stage malaria vaccine trial

PLoS Medicine

Volumn 2, Issue 11, 2005, Pages 1078-1079

  Crabb, Brendan S ^a   Beeson, James G ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT;

ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CLINICAL TRIAL; DRUG RESEARCH; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; INTRACELLULAR KILLING; LARVAL STAGE; MALARIA FALCIPARUM; MOLECULAR RECOGNITION; PARASITE VIRULENCE; PLASMODIUM FALCIPARUM; PROTEIN FAMILY; SEROCONVERSION; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; ANIMAL; ARTICLE; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; PATHOGENICITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; CLINICAL TRIALS AS TOPIC; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 28444496053     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020380     Document Type: Short Survey

References (12)

1. Sachs J, Malaney P (2002) The economic and social burden of malaria. Nature 415: 680-685.
2. Cowman AF, Crabb BS (2002) The Plasmodium falciparum genome - A blueprint for erythrocyte invasion. Science 298: 126-128.
3. Druilhe P, Spertini F, Soe S, Corradin G, Mejia P, et al. (2005) A malaria vaccine that elicits in humans antibodies able to kill P. falciparum. PLoS Med 2: e344. DOI: 10.1371/journal.pmed.0020344
4. McColl DJ, Silva A, Foley M, Kun JF, Favaloro JM, et al. (1994) Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol 68: 53-67.
5. Pearce JA, Mills K, Triglia T, Cowman AF, Anders RF (2005) Characterisation of two novel proteins from the asexual stage of Plasmodium falciparum, H101 and H103. Mol Biochem Parasitol 139: 141-151.
6. Mills KE, Pearce JA, Crabb BS, Cowman AF (2002) Truncation of merozoite surface protein 3 disrupts its trafficking and that of acidic-basic repeat protein to the surface of Plasmodium falciparum merozoites. Mol Microbiol 43: 1401-1411.
7. Luty AJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, et al. (1999) Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis 179: 980-988.
8. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, et al. (2002) Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360: 610-617.
9. Guevara-Patiño JA, Holder AA, McBride JS, Blackman MJ (1997) Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med 186: 1689-1699.
10. John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, et al. (2004) Evidence that invasion-inhibitory antibodies specific for MSP-1(19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 173: 666-672.
11. Egan AF, Burghaus PA, Druilhe P, Holder AA, Riley EM (1999) Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol 21: 133-139.
12. O'Donnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, et al. (2001) Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasioninhibitory response in individuals immune to malaria. J Exp Med 193: 1403-1412.